down-arrow icon pointed-base

Investment Potential

Financing Strategy:

Please visit our crowdfunding campaign site: https://www.gofundme.com/marvelmedtech4change

Marvel Medtech has raised nearly $2,500,000 of capital to date, including nearly $2M in federal SBIR grant awards from the National Cancer Institute/National Institutes of Health (NCI/NIH).  The Company is presently seeking Series A equity financing of $6M to rapidly complete product development, regulatory compliance (FDA and CE, etc.) and launch commercial sales.

Additional financing of $7 – $10 million is projected to get the company to sustainable growth, achieving positive cash flow results in 4-5 years.

Wisconsin Investor Tax Credits:

Marvel Medtech has been certified as a “qualified new business venture”, making investors with Wisconsin tax liabilities eligible for up to $1.25 million of State investor tax credits.

Exit Strategy:

There are well-established recent precedents for acquisition of imaging accessory technology companies such as Marvel Medtech by existing medical imaging OEM (e.g. GE Healthcare, Siemens, Philips) or imaging / interventional technology companies (e.g. Hologic, Devicore, CR Bard). Recent comparable acquisitions of companies similar to Marvel Medtech establish that returns for early investors of 25x to 40x their initial investments have been achieved.

Marvel Medtech anticipates becoming a very attractive acquisition target once our initial product is demonstrated as clinically effective and practical, possibly as soon as initial clinical results are reported in year 2 or 3 (i.e. potentially before Series B funding is needed), but more likely as we begin to achieve noteworthy market traction in year 4-6.  Depending upon timing and other decisions, Marvel Medtech’s pro forma financial modeling projects an estimated return of 25x for early-stage investors.